Evidence map›Paper›PMID 40383862›Full record

Trial reportScientific reports2025

Diverse Lenabasum pathway activation in dermatomyositis patients' blood.

Nilesh Kodali, DeAnna Diaz, Rohan Dhiman, Thomas Vazquez, Rui Feng, Jay Patel, Joshua Dan, Grant Sprow, Julianne Kleitsch, Meena Sharma and 2 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nilesh KodaliDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
DeAnna DiazDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Rohan DhimanDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Thomas VazquezDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Rui FengDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Jay PatelDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Joshua DanDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Grant SprowDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Julianne KleitschDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Meena SharmaDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Muhammad BashirDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Victoria P WerthDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. werth@pennmedicine.upenn.edu.

Funding

Study Design and Data AnalysisP30AR069589 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice · 2016 to 2026
$8.6M
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositisR01AR076766 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI WERTH, VICTORIA P · 2020 to 2023
$1.7M
Treatment of Dermatomyositis with Ajulemic Acid, a Non-Psychoactive CannabinoidR21AR066286 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI WERTH, VICTORIA P · 2014 to 2016
$387k
BLRD VA I01 BX005921NIAMS NIH HHS P30 AR069589NIAMS NIH HHS R01 AR076766NIAMS NIH HHS R21 AR066286NIH HHS R21AR066286Penn Skin Biology and Diseases Resource-based Center, University of Pennsylvania P30AR069589-01U.S. Department of Veterans Affairs 1I01BX005921
6 · The paper itself

Abstract

Lenabasum, a non-psychoactive cannabinoid type-2 receptor (CB2R) agonist, has shown promise in reducing cutaneous disease in Dermatomyositis (DM) patients. Lenabasum activates two distinct receptors: CB2R and the nuclear peroxisome proliferator-activated receptor-γ (PPARγ). Our goal was to investigate the dominant mechanism of action leading to pathogenic IFNβ reduction by lenabasum (through CB2R or PPARγ) across leukocytes. We utilized whole blood leukocytes from 14 DM patients and grouped patients as in vitro responders or non-responders. We stimulated leukocytes in vitro in the presence of CB2R and PPARγ inhibitors and lenabasum. Intracellular and extracellular marker expression was analyzed by flow cytometry. CD4

Indexed as

DermatomyositisReceptor, Cannabinoid, CB2Signal TransductionAdultAgedFemaleHumansLeukocytesMaleMiddle AgedMonocytesPPAR gammaPPAR gammaReceptor, Cannabinoid, CB2DermatomyositisFlow cytometryIFNβLenabasumMechanism

Identifiers

PMID40383862
PMCPMC12086228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.